Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) Net Margin (2016 - 2025)

Historic Net Margin for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to 13.76%.

  • Ascendis Pharma A's Net Margin rose 83600.0% to 13.76% in Q4 2025 from the same period last year, while for Dec 2025 it was 20.27%, marking a year-over-year decrease of 1038700.0%. This contributed to the annual value of 32.16% for FY2025, which is 718100.0% up from last year.
  • According to the latest figures from Q4 2025, Ascendis Pharma A's Net Margin is 13.76%, which was up 83600.0% from 29.29% recorded in Q3 2025.
  • Over the past 5 years, Ascendis Pharma A's Net Margin peaked at 13148.14% during Q2 2021, and registered a low of 8417.16% during Q1 2021.
  • Moreover, its 5-year median value for Net Margin was 29.24% (2023), whereas its average is 247.3%.
  • The largest annual percentage gain for Ascendis Pharma A's Net Margin in the last 5 years was 65791700bps (2022), contrasted with its biggest fall of -118157400bps (2022).
  • Quarter analysis of 5 years shows Ascendis Pharma A's Net Margin stood at 123.14% in 2021, then crashed by -636bps to 905.96% in 2022, then soared by 97bps to 29.19% in 2023, then increased by 24bps to 22.12% in 2024, then skyrocketed by 38bps to 13.76% in 2025.
  • Its last three reported values are 13.76% in Q4 2025, 29.29% for Q3 2025, and 25.47% during Q2 2025.